Advaccine

Advaccine is an innovative vaccine company with a high-value prophylactic and therapeutic vaccine pipeline driven by in-house developed technology platforms and industrial manufacturing capabilities. Its pipeline consists of potential first-in-class key assets developed to address diseases caused by SARS-CoV-2, respiratory syncytial virus (RSV), and hepatitis B virus (HBV), which are diseases with huge unmet medical needs. Advaccine is also developing a series of cancer vaccine candidates, covering viral-related oncology, neoantigen-based therapeutic vaccines, and tumor-associated antigen therapeutic vaccines. Founded in 2009, the company aims to revolutionize vaccine development and manufacture high-impact interventions. However, specific information about its industries, headquarters, last investment, and investors is currently unavailable. The pioneering approach and focus on crucial healthcare challenges position Advaccine as a potential game-changer in the biotech and pharmaceutical industries.